Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma

Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) with aggressive disease characteristics resulting in multiple relapses after initial treatment. Lenalidomide is an immunomodulatory agent approved in the US for patients with relapsed/refractory MCL following bortezomib based on resu...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Hematol
Asıl Yazarlar: Witzig, Thomas E., Zinzani, Pier Luigi, Habermann, Thomas M., Tuscano, Joseph M., Drach, Johannes, Ramchandren, Radhakrishnan, Besisik, Sevgi Kalayoglu, Takeshita, Kenichi, Bravo, Marie-Laure Casadebaig, Zhang, Lei, Fu, Tommy, Goy, Andre
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6896320/
https://ncbi.nlm.nih.gov/pubmed/28699256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24854
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller